Want to see AU:SPL full AI Analyst Report?
SPL Stock Chart & Stats
AU$0.72
AU$0.00(0.00%)
At close: 4:00 PM EDT
AU$0.72
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.24 - AU$0.88
Previous CloseN/A
Volume2.10M
Average Volume (3M)2.25M
Market Cap
AU$415.04M
Enterprise ValueAU$284.34
Total Cash (Recent Filing)AU$11.02M
Total Debt (Recent Filing)AU$707.00K
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Mar 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding477,054,960
10 Day Avg. Volume2,621,454
30 Day Avg. Volume2,252,984
Financial Highlights & Ratios
PEG Ratio1.43
Price to Book (P/B)21.33
Price to Sales (P/S)24.38
P/FCF Ratio-84.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$24.00M
Bulls Say, Bears Say
Bulls Say
Diversified Dendrimer Commercialisation ModelStarpharma has multiple routes to commercialisation through its DEP® partnering platform and VivaGel®/Astodrimer Sodium products. This combination can support licensing, milestone, royalty, supply, and product revenue, reducing reliance on one asset or revenue channel over the medium term.
Material Debt ReductionThe sharp reduction in debt materially lowers financial risk and should reduce refinancing pressure and interest-related constraints. A lightly leveraged balance sheet gives Starpharma greater flexibility to direct available resources toward development and commercialisation priorities over the next several quarters.
Improving Cash BurnAlthough cash flow remains negative, the significant improvement in 2026 burn indicates progress toward better financial efficiency. If maintained, lower outflows could extend funding capacity and reduce the urgency of external financing while partnered and commercial programs develop.
Bears Say
Persistent Operating LossesStarpharma remains materially unprofitable despite generating A$10.4m of gross profit in 2026. Continued negative EBIT, EBITDA, and net income show that operating costs still exceed earnings from the business, limiting self-funded investment and leaving profitability dependent on future commercial progress.
Negative Free Cash FlowPersistent negative operating and free cash flow means the company is not yet self-funding its operations. Even with improved 2026 cash burn, ongoing outflows can require additional funding if profitability does not improve, potentially constraining development spending and strategic flexibility.
Eroding Equity BaseThe substantial decline in equity reflects the cumulative effect of ongoing losses and cash burn. A smaller capital base reduces balance-sheet resilience and limits flexibility compared with earlier years, increasing the importance of achieving sustainable profitability or securing further funding.
Starpharma Holdings Limited News
SPL FAQ
What was Starpharma Holdings Limited’s price range in the past 12 months?
Starpharma Holdings Limited lowest share price was AU$0.24 and its highest was AU$0.88 in the past 12 months.
What is Starpharma Holdings Limited’s market cap?
Starpharma Holdings Limited’s market cap is AU$415.04M.
When is Starpharma Holdings Limited’s upcoming earnings report date?
Starpharma Holdings Limited’s upcoming earnings report date is Mar 02, 2027 which is in 151 days.
How were Starpharma Holdings Limited’s earnings last quarter?
Starpharma Holdings Limited released its earnings results on Aug 25, 2026. The company reported -AU$0.02 earnings per share for the quarter.
Is Starpharma Holdings Limited overvalued?
According to Wall Street analysts Starpharma Holdings Limited’s price is currently Overvalued.
Does Starpharma Holdings Limited pay dividends?
Starpharma Holdings Limited does not currently pay dividends.
What is Starpharma Holdings Limited’s EPS estimate?
Starpharma Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Starpharma Holdings Limited have?
Starpharma Holdings Limited has 477,054,960 shares outstanding.
What happened to Starpharma Holdings Limited’s price movement after its last earnings report?
Starpharma Holdings Limited reported an EPS of -AU$0.02 in its last earnings report. Following the earnings report the stock price went down -0.685%.
Which hedge fund is a major shareholder of Starpharma Holdings Limited?
Currently, no hedge funds are holding shares in AU:SPL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Starpharma Holdings Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:SPL Sentiment 100%
Sector Average 65%
Sector Average 65%
Insider Transactions
Bought Shares
Worth AU$309.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
505.26%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-20.92%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Starpharma Holdings Limited
Starpharma Holdings Limited is a biopharmaceutical enterprise focused on the research, development, and global commercialization of dendrimer-based products for the pharmaceutical, life sciences, and other industries. Its current offerings include VivaGel, a non-antibiotic treatment and preventative measure for bacterial vaginosis. The company also provides the antiviral VivaGel condom and VIRALEZE, an antiviral nasal spray. Furthermore, Starpharma is actively progressing its DEP (dendrimer drug delivery) technology platform. This platform supports multiple oncology candidates in clinical development, such as DEP docetaxel (Phase 2), DEP cabazitaxel (Phase 2), DEP gemcitabine (Phase 1/2), and DEP irinotecan (Phase 2), all aimed at treating cancer. The DEP technology is also being applied to radiotheranostics for cancer diagnosis and therapy, Antibody Drug Conjugates (including DEP HER-2 ADC), and non-oncology programs. Additionally, DEP AZD0466 is currently in Phase 1/2 clinical trials for haematological malignancies. Founded in 1996, the company maintains its headquarters in Abbotsford, Australia.
Technical Analysis
Immutep Ltd
―
Dimerix Limited
―
AnteoTech Ltd
―
Botanix Pharmaceuticals Limited
―
Recce Pharmaceuticals Ltd.
―